ArticleMicrosystems & nanoengineering2021
A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection.
Article in Microsystems & nanoengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- An Edible HAdvanced healthcare materials · 2026Article
- Rapid detection and quantification of glyphosate in water using a handheld portable biosensor.Scientific reports · 2026Article
- Nanoformulation-assisted early diagnosis of prostate cancer: Advances and perspectives.Biomaterials translational · 2025Article
- Microfluidic Applications in Prostate Cancer Research.Micromachines · 2024Review
- Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024Review
- A closed-loop catalytic nanoreactor system on a transistor.Science advances · 2023Article
- Metabolomics in pediatric lower respiratory tract infections and sepsis: a literature review.Pediatric research · 2023Review
- Laser-assisted protein micropatterning in a thermoplastic device for multiplexed prostate cancer biomarker detection.Lab on a chip · 2023Article
- Point-of-Care Platform for Diagnosis of Venous Thrombosis by Simultaneous Detection of Thrombin Generation and D-Dimer in Human Plasma.Analytical chemistry · 2023Article
- Integrating Microfluidics and Electronics in Point-of-Care Diagnostics: Current and Future Challenges.Micromachines · 2022Review
- Simplifying the complex: accessible microfluidic solutions for contemporary processes withinLab on a chip · 2022Review
- A Hybrid Microfluidic Electronic Sensing Platform for Life Science Applications.Micromachines · 2022Article
- Factor VIII companion diagnostic for haemophilia.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
There is a global unmet need for rapid and cost-effective prognostic and diagnostic tools that can be used at the bedside or in the doctor's office to reduce the impact of serious disease. Many cancers are diagnosed late, leading to costly treatment and reduced life expectancy. With prostate cancer, the absence of a reliable test has inhibited the adoption of screening programs. We report a microelectronic point-of-care metabolite biomarker measurement platform and use it for prostate cancer detection. The platform, using an array of photodetectors configured to operate with targeted, multiplexed, colorimetric assays confined in monolithically integrated passive microfluidic channels, completes a combined assay of 4 metabolites in a drop of human plasma in under 2 min. A preliminary clinical study using l-amino acids, glutamate, choline, and sarcosine was used to train a cross-validated random forest algorithm. The system demonstrated sensitivity to prostate cancer of 94% with a specificity of 70% and an area under the curve of 0.78. The technology can implement many similar assay panels and hence has the potential to revolutionize low-cost, rapid, point-of-care testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.